This is an open-label, multi-center, dose-escalation trial of pimasertib (MSC1936369B) in
blood and bone marrow cancers. The trial will be conducted in two parts:
Part 1 (safety run-in period): Will determine the maximum tolerated dose (MTD) of the study
drug in subjects with advanced hematological malignancies.
Part 2: Will assess the anti-leukemic activity of the study drug in older subjects with newly
diagnosed poor prognosis acute myeloid leukemia (AML) who are not candidates for intensive
chemotherapy.